[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc reports the purchase and cancellation of 1,200,000 ordinary shares under the second tranche of its share buyback programme announced 31 July 2025. After settlement the company's registered share capital is 8,954,414,051 ordinary shares of £0.01 each, with 1,580,205 held as treasury shares, leaving 8,952,833,846 ordinary shares with voting rights. The announcement notes a full breakdown of individual trades is available via the provided link and on the company website. The notice clarifies it is not an offer for securities and provides contact/signature details for the company secretary.

Positive

• Share repurchase executed: Purchase and cancellation of 1,200,000 ordinary shares completed under the announced buyback programme
• Updated capital disclosure: Registered share capital and number of voting shares provided, aiding shareholder notification calculations
• Regulatory transparency: Full breakdown of individual trades made available in line with Market Abuse Regulation requirements

Negative

• None.

Insights

Financial Analyst

TL;DR: Company executed a modest tranche of its announced buyback, updating shares outstanding and voting rights.

The company purchased and cancelled 1.2 million shares under a previously announced buyback programme. This reduces issued share capital to 8.954 billion and leaves 8.9528 billion voting shares. The transaction size is small relative to total share count, so near-term EPS impact will be minimal. Disclosure includes a trade-level breakdown link consistent with market abuse regulation transparency requirements.

Corporate Governance Expert

TL;DR: Proper regulatory disclosure of share repurchase and updated share capital; routine governance compliance.

The filing follows required transparency protocols by stating shares bought for cancellation, updated capital figures, and providing an itemized trade breakdown. It confirms retained treasury shares and supplies the voting-share figure investors use for notification thresholds. The announcement explicitly disclaims an offer for securities, aligning with standard governance practice.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	09 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

09 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,200,000 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	08 September 2025	08 September 2025	08 September 2025
Number of Shares purchased:	1,200,000	-	-
Highest price paid per Share (p):	363.6000	-	-
Lowest price paid per Share (p):	358.4000	-	-
Volume weighted average price paid per Share (p):	360.6643	-	-

Following the settlement of the above, the Company's registered share capital is 8,954,414,051 ordinary shares of £0.01 each, of which 1,580,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,952,833,846 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/4892Y_1-2025-9-8.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 09, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What shares did Haleon (HLN) purchase in this 6-K?

Haleon purchased and cancelled 1,200,000 ordinary shares of £0.01 each under its second tranche buyback.

How many Haleon shares are outstanding and have voting rights after this transaction?

After settlement the company has 8,954,414,051 registered ordinary shares, with 1,580,205 held as treasury shares, leaving 8,952,833,846 voting shares.

Where can I find the detailed trade breakdown for the buyback?

A full breakdown of individual trades is available at the provided London Stock Exchange link and on www.haleon.com/investors.

Does this announcement constitute an offer for securities?

No. The announcement explicitly states it does not constitute or form part of any offer or solicitation for securities.

Was this buyback part of a previously announced programme?

Yes. The purchases were made under the second tranche of the share buyback programme announced on 31 July 2025.